OTCMCSBTF
Market cap846mUSD
Dec 11, Last price
22.57USD
Name
Kuros Biosciences AG
Chart & Performance
Profile
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.
Valuation
Title CHF in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 33,564 86.61% | 17,986 30.19% | 13,815 242.04% | |||||||
Cost of revenue | 35,918 | 23,564 | 16,119 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (2,354) | (5,578) | (2,304) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 380 | (1,396) | (2,013) | |||||||
Tax Rate | ||||||||||
NOPAT | (2,734) | (4,182) | (291) | |||||||
Net income | (13,727) -5.95% | (14,595) 93.54% | (7,541) -34.54% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 501 | 6,000 | ||||||||
BB yield | -0.39% | -12.04% | ||||||||
Debt | ||||||||||
Debt current | 578 | 416 | 317 | |||||||
Long-term debt | 3,708 | 3,410 | 3,975 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | (5,073) | 353 | ||||||||
Net debt | (14,364) | (71,288) | (77,795) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (8,844) | (7,348) | (5,453) | |||||||
CAPEX | (317) | (400) | (374) | |||||||
Cash from investing activities | (326) | (400) | (374) | |||||||
Cash from financing activities | (171) | 3,224 | 6,078 | |||||||
FCF | (3,430) | (4,058) | 1,832 | |||||||
Balance | ||||||||||
Cash | 14,208 | 24,065 | 28,623 | |||||||
Long term investments | 4,442 | 51,049 | 53,464 | |||||||
Excess cash | 16,972 | 74,215 | 81,396 | |||||||
Stockholders' equity | (16,587) | (91,699) | (77,176) | |||||||
Invested Capital | 75,442 | 157,399 | 156,651 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 36,582 | 33,901 | 32,794 | |||||||
Price | 3.49 137.41% | 1.47 -23.64% | 1.93 -4.70% | |||||||
Market cap | 127,671 156.19% | 49,834 -21.06% | 63,129 28.52% | |||||||
EV | 113,307 | (21,454) | (14,666) | |||||||
EBITDA | 398 | (2,744) | 576 | |||||||
EV/EBITDA | 284.69 | 7.82 | ||||||||
Interest | 186 | 4,317 | 1,383 | |||||||
Interest/NOPBT |